Literature DB >> 8321983

Nasal distribution of budesonide inhaled via a powder inhaler.

L Thorsson1, S P Newman, A Weisz, E Trofast, F Morén.   

Abstract

The distribution pattern of budesonide in the nasal passages and lungs was investigated in 10 healthy subjects after nasal inhalation. The subjects inhaled drug powder, radiolabelled with 99mTc, at maximum flow rate (46.3 +/- 6.8 l/min) and at 29.9 +/- 2.5 l/min via Turbuhaler. At both flows, the majority of the dose was deposited in the anterior part of the nasal cavity on a single, rather localized area, but some particles also penetrated more posteriorly into the main nasal passages and to the lungs. At maximum flow rate the nasal deposition was 65.2% (range 39.5-84.1%) and the lung deposition 4.7% (range 1.4-9.3%) of the metered dose, and at 30 l/min, the nasal deposition was 67.6% (range 49.7-81.6%) and the lung deposition was 4.2% (range 1.7-7.9%). A large fraction of the metered dose was deposited in the nasal adaptor of the inhaler during the administration (mean values 29 and 28%, for the two inhalation flows). Of the dose actually reaching the subject, 91 and 93% (mean values) was deposited in the nose. There were no statistically significant differences in distribution pattern between the two inhalation flows.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8321983

Source DB:  PubMed          Journal:  Rhinology        ISSN: 0300-0729            Impact factor:   3.681


  6 in total

1.  Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous pump spray, and powder.

Authors:  L Thorsson; O Borgâ; S Edsbäcker
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

Review 2.  Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis.

Authors:  Rami Jean Salib; Peter Hugo Howarth
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

3.  Measurement of drug in small particles from aqueous nasal sprays by Andersen Cascade Impactor.

Authors:  William H Doub; Wallace P Adams; Anna M Wokovich; John C Black; Meiyu Shen; Lucinda F Buhse
Journal:  Pharm Res       Date:  2012-07-03       Impact factor: 4.200

Review 4.  Mechanisms of pharmaceutical aerosol deposition in the respiratory tract.

Authors:  Yung Sung Cheng
Journal:  AAPS PharmSciTech       Date:  2014-02-22       Impact factor: 3.246

Review 5.  Studies using radiolabelled aerosols in children.

Authors:  M L Everard
Journal:  Thorax       Date:  1994-12       Impact factor: 9.139

6.  Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review.

Authors:  Per Gisle Djupesland
Journal:  Drug Deliv Transl Res       Date:  2012-10-18       Impact factor: 4.617

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.